Introduction: A new benchmark in melanoma risk assessment Recent analyses from SkylineDx present compelling evidence that the Merlin CP-GEP Test offers superior metastatic-risk stratification for melanoma compared with benchmarks released by a major competitor. In a field where precise risk categorization directly informs surgical decisions and patient outcomes, these findings could influence standard-of-care considerations for…